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AICAR = aminoimidazolecarboxamidoribonucleotide; Fc = crystallizable fragment (of antibody); IFN = interferon; IL = interleukin; RA = rheumatoid
arthritis; Th = T helper (cells); TNF = tumor necrosis factor.
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Introduction
The demonstration in 1985 that low-dose, intermittent
methotrexate is a potent and effective therapy for rheuma-
toid arthritis (RA) [1] led to a dramatic change in the way
that patients with RA are treated. Indeed, methotrexate is
no less efficacious than specific anti-tumor-necrosis-factor
(anti-TNF) therapy for the relief of symptomatic joint inflam-
mation in early RA, and the difference between methotrex-
ate and etanercept with respect to protection from
structural injury in RA is probably not biologically signifi-
cant [2]. Thus, methotrexate remains the cornerstone of
therapy for RA, and understanding the mechanism(s)
responsible for the therapeutic efficacy of this agent may
lead to the development of new therapies.
History and clinical pharmacology
Methotrexate was first developed in the 1940s as a spe-
cific antagonist of folic acid. This drug inhibits the prolifera-
tion of malignant cells, primarily by inhibiting the de novo
synthesis of purines and pyrimidines. Because administra-
tion of high doses of reduced folic acid (folinic acid) or
even folic acid itself can reverse the antiproliferative effects
of methotrexate, it is clear that methotrexate does act as an
antifolate agent. Interestingly, although not originally
designed as such, methotrexate appears to be a ‘pro-drug’,
i.e. a compound that is converted to the active agent after
uptake. Methotrexate is taken up by cells via the reduced
folate carrier and then is converted within the cells to
polyglutamates [3]. Methotrexate polyglutamates are long-
lived metabolites that retain some of the antifolate activities
of the parent compound, although the potency for inhibition
of various folate-dependent enzymes is shifted [3–6].
Proposed mechanisms of action of
methotrexate
Low-dose methotrexate was introduced for the treatment
of RA because of its presumed antiproliferative properties,
although it was unclear how inhibiting proliferation of the
lymphocytes thought to be responsible for synovial inflam-
mation in RA for one day a week might lead to effective
suppression of disease activity. However, it soon became
clear that inhibition of folic acid metabolism could not be
completely responsible for the anti-inflammatory effect of
methotrexate. During the past 15 years, it has become
clear that administration of folic acid in doses of 1–5 mg
per day helps to prevent much of the toxicity of methotrex-
ate without interfering with the anti-inflammatory efficacy
of the drug, whereas very high doses of folinic acid also
prevent methotrexate toxicity but may interfere with its effi-
cacy [7–20]. There are two potential explanations for the
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Abstract
Despite the recent introduction of biological response modifiers and potent new small-molecule
antirheumatic drugs, the efficacy of methotrexate is nearly unsurpassed in the treatment of inflammatory
arthritis. Although methotrexate was first introduced as an antiproliferative agent that inhibits the
synthesis of purines and pyrimidines for the therapy of malignancies, it is now clear that many of the anti-
inflammatory effects of methotrexate are mediated by adenosine. This nucleoside, acting at one or more
of its receptors, is a potent endogenous anti-inflammatory mediator. In confirmation of this mechanism of
action, recent studies in both animals and patients suggest that adenosine-receptor antagonists, among
which is caffeine, reverse or prevent the anti-inflammatory effects of methotrexate.
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capacity of high doses of folinic acid to reverse the thera-
peutic effects: first, folinic acid may bypass the effects of
methotrexate on reduction of folic acid and thereby
bypass the therapeutic effects of the drug; alternatively,
folinic acid but not folic acid may compete with methotrex-
ate for a single transport site into the cell (Fig. 1) and may
thus interfere with cellular uptake of methotrexate [21].
Moreover, the expected inhibition of cellular proliferation is
manifested as bone marrow suppression, and oral and gas-
trointestinal ulcers, and may require lowering the dose of
the drug and, usually, the efficacy of the therapy, suggesting
that inhibition of cellular proliferation alone is not responsi-
ble for the anti-inflammatory effects of methotrexate. Thus,
folate antagonism appears to play, at most, a minimal role in
the anti-inflammatory mechanism of methotrexate.
Another potential mechanism by which methotrexate may
diminish inflammation in the joint is by diminishing cytokine
production. Numerous studies have demonstrated dimin-
ished levels of inflammatory cytokines in the serum of
patients. The adenosine A2A receptor agonist CGS-21680
is a potent inhibitor of neutrophil leukotriene synthesis in
vitro, and, similarly, methotrexate therapy leads to dimin-
ished production of leukotriene B4 by neutrophils stimulated
ex vivo [22,23]. The mechanism by which methotrexate
diminishes these cytokine levels remains unexplained and it
is difficult to determine from these studies whether the
effects of methotrexate therapy on production of inflamma-
tory mediators results in diminished inflammation or is sec-
ondary to other anti-inflammatory events.
Similarly, methotrexate-mediated effects on T-cell function,
either in vivo or in vitro, have been demonstrated. Indeed,
Genestier and colleagues have reported that methotrexate
diminishes antigen-stimulated T-cell proliferation both in
vitro and in T cells taken from patients taking methotrexate
[24]. That the effects of methotrexate on T-cell function
are completely reversed by folic acid and that the effects
of therapy on T cells studied ex vivo are present for only
48 hours a week would strongly suggest that this cannot
be responsible for the bulk of the anti-inflammatory effects
of the drug.
A third proposed mechanism of action is based upon the
observation that polyamines accumulate in the synovium
of patients with RA and that metabolism of these
polyamines by macrophages leads to the production of
toxic oxygen products that diminish stimulated T-cell func-
tion [25–27]. Indeed, methotrexate therapy does diminish
polyamine levels in the joints of patients with RA [28–30],
but this effect, like that of methotrexate on T-cell prolifera-
tion, is reversed by folic acid. Moreover, there are more
than enough toxic oxygen metabolites being generated in
the rheumatoid synovium to mediate the tissue damage
present in this disease; another source of toxic agents
would add relatively little.
Methotrexate induces adenosine release
Our laboratory originally proposed the hypothesis that the
beneficial effects of methotrexate result from the intracellu-
lar accumulation of intermediates in purine biosynthesis
that, by a mechanism that has not been completely
worked out, leads to increased concentrations of adeno-
sine in the extracellular space [31]. This hypothesis
sprang from the prior demonstration that intracellular
accumulation of specific intermediates in the de novo syn-
thesis of purines leads to adenosine release [32] and from
our interest in the anti-inflammatory effects of adenosine,
which are mediated by specific receptors on inflammatory
cells. Prior work had demonstrated that methotrexate
polyglutamates inhibit the enzyme aminoimidazolecarbox-
amidoadenosineribonucleotide (AICAR) transformylase
more potently than the other enzymes involved in purine
biosynthesis [4,5,33]. This inhibition occurred at pharma-
cologically relevant concentrations of methotrexate and
might be expected to occur more readily with infrequent
loading with methotrexate, since methotrexate polygluta-
mates are long-lived metabolites (persisting for weeks).
The presence of increased concentrations of AICAR
metabolites in the urine of RA patients treated with
methotrexate supports these findings [34,35]. The accu-
mulation of AICAR and its metabolites has a direct
inhibitory effect on at least two key enzymes, adenosine
deaminase and AMP deaminase, with the end result of
increased concentrations of adenosine and adenine
nucleotides intracellularly [4]. Methotrexate in doses
similar to that used in the treatment of RA has been known
Figure 1
Methotrexate-induced metabolic changes lead to increased extra-
cellular adenosine. ADA = adenosine deaminase; AICAR = amino-
imidazolecarboxamidoribonucleotide; AICAside = aminoimidazole-
carboxamidoribonucleoside; AK = adenosine kinase; AMPDA = AMP
deaminase; DHF = dihydrofolate; DHFglu = dihydrofolate
polyglutamate; ecto-5′NT = ecto-5′nucleotidase; FAICAR = formyl-
AICAR; IMP = inosine monophosphate; MTX = methotrexate; MTXglu =
methotrexate polyglutamate; RFC1 = reduced folate carrier 1.268
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to cause the accumulation of AICAR in animal models of
RA, and this accumulation is associated with an elevation
in adenosine concentration in the extracellular space
[32,36]. The exact mechanisms by which the elevation of
extracellular adenosine arises are not fully understood, but
dephosphorylation of adenine nucleotides is likely to be a
major contributor, partly because of the ubiquitous nature
of ATP in tissues and partly because of the widespread
existence of ecto-5′-nucleotidase, an enzyme that cat-
alyzes the dephosphorylation of AMP to adenosine [37].
All this evidence points to adenosine as a key mediator in
the anti-inflammatory actions of methotrexate. In vivo exper-
iments support this contention. The nonselective adeno-
sine receptor antagonist 8-phenyl theophylline potentiated
inflammatory responses in a hamster-cheek-pouch model
[38]. Infusion of adenosine directly into the knee in rats
inhibited the development of adjuvant-induced arthritis, and
an adenosine receptor antagonist effectively reduced the
severity of joint inflammation in a collagen-induced arthritis
model in mice [39,40]. We have previously shown that the
anti-inflammatory effects of methotrexate in carrageenan-
induced mouse air pouch inflammation is reversed by an
antagonist to the adenosine A2A receptor, or by the addi-
tion of adenosine deaminase, an adenosine-metabolizing
enzyme, suggesting that adenosine is indeed responsible
for the anti-inflammatory effects of methotrexate in vivo
[36]. An interesting study by Silke et al. showed that inges-
tion of caffeine, a nonselective antagonist of adenosine
receptors, in coffee correlates with poor clinical response
to methotrexate, and patients with a high caffeine intake are
more likely to discontinue methotrexate than those with a
low caffeine intake [41].
To better appreciate how adenosine influences biological
responses in the network of events taking place in an
inflammatory milieu, something must be said about this
autocoid and the cellular receptors with which it interacts
to produce these physiological responses. Adenosine
receptors, or P1 receptors, fall into four known subclasses:
A1, A2A, A2B, and A3. These are members of the large,
seven-transmembrane-receptor family of receptors that
influence cell signaling mechanisms by coupling to G pro-
teins. The receptor sequences have been characterized
and, with the exception of the A3 receptor, they are highly
conserved during evolution. Adenosine receptors modulate
a vast array of physiological functions, from heart rate to
the state of wakefulness. Adenosine, acting on P1 recep-
tors, exerts a number of actions on a variety of cell types
relevant to the anti-inflammatory effect of methotrexate.
Cellular effects
Neutrophils
Neutrophils, a hallmark of acute inflammation, are among
the first cells recruited into the inflammatory site. The limi-
tation of neutrophilic-mediated damage relies in part on
the modification of the adhesive capacity and ability to
generate chemical damage, properties under purinergic
influence. The resting neutrophil has a number of mecha-
nisms that, once activated, can damage tissues. One of
these is latent nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase, a multimolecular complex that is
assembled at the plasma membrane upon activation of the
neutrophil and that generates oxygen radicals [42]. The
first in the chain of these oxygen radicals is superoxide
anion, and it was the discovery in 1983 that superoxide
generation, as stimulated by a variety of agents including
the chemoattractant N-formyl-leucyl-phenylalanine (fMLP),
the complement component C5a, and the calcium
ionophore A23187, was inhibited by adenosine that
sparked an interest in the anti-inflammatory properties of
adenosine [43,44]. This physiological action of adenosine
has subsequently been ascribed to its action on the
adenosine A2A receptor, which is present on the neu-
trophilic surface membrane [45]. An important second
messenger to adenosine-A2A-receptor signaling in this
respect appears to be 3′,5′-cyclic adenosine monophos-
phate (cAMP), the intracellular concentration of which
increases with neutrophilic adenosine A2A receptor stimu-
lation. cAMP further activates protein kinase A down-
stream and inhibition of protein kinase A reverses the
effects of cAMP analogues but not of adenosine receptor
agonists on stimulated neutrophilic superoxide anion gen-
eration [46]. The cAMP–protein-kinase-A-dependent
adenosine inhibition of neutrophil oxidative activity is medi-
ated via the adenosine A2A receptor [47]. One direct con-
sequence of the interruption of superoxide anion formation
and respiratory burst reactions is the protection of vascu-
lar endothelial cells from neutrophil-mediated injury [48].
The adenosine-A2A-receptor-mediated effects on neutro-
phil function are dose-related. At concentrations similar to
those required to inhibit the release of superoxide anions,
adenosine, acting through A2A receptors, inhibits adher-
ence to endothelial cells by stimulated neutrophils [49].
This may be related in part to dose-related preferential
recruitment of receptor subtype, since the adenosine A1
receptor exhibits many opposing physiological functions
to those mediated by the A2A receptor, including stimula-
tion of neutrophil adherence to endothelial cells. Adeno-
sine also inhibits the release of vascular endothelial
growth factor from neutrophils, thereby enhancing vascu-
lar permeability [50]. The dose-dependent response in
adenosine action is also seen with Fc-gamma-receptor-
mediated neutrophil phagocytosis, which is enhanced by
A1 receptor stimulation but inhibited via A2 receptors [51].
In addition, adenosine also inhibits the TNF-induced gen-
eration of elastase by neutrophils [52].
Expression of adhesive molecules is an important event
that guides neutrophil recruitment into an inflammatory
site through adhesion to the vascular endothelium.269
Adenosine has been known to be a modulator of the
expression or function of adhesive molecules including
β2-integrin, L-selectin, and CD11b/CD18 [49,53,54]. The
activity of adenosine in the modulation of neutrophil adhe-
sion again demonstrates the opposing roles of A1 and A2
receptors [49].
Macrophages
Cells of the monocyte–macrophage series are abundant
in the rheumatoid synovium and pannus and contribute
significantly to the tissue damage seen in both acute and
chronic disease, as recently reviewed by Kinne and col-
leagues [55]. Macrophages, the differentiated tissue form,
are also critical producers of cytokines that play a promi-
nent role in promoting proinflammatory responses that cul-
minate in tissue damage. Like neutrophils, their capacity to
phagocytose opsonized particles and to generate super-
oxide anions plays a major role in eliciting tissue damage.
Inhibition of Fc-gamma-receptor phagocytic activity in cul-
tured monocytes is exhibited by adenosine at high con-
centrations such as that seen with tissue damage and is a
function mediated via adenosine A2 receptors, while low
concentrations of adenosine have the opposite effect on
Fc-gamma-receptor phagocytic activity mediated via
adenosine A1 receptors [56]. Similarly, adenosine inhibits
the generation of superoxide anions by monocytes stimu-
lated with N-formyl-leucyl phenylalanine [57].
One of the well known though uncommon side effects of
methotrexate treatment is the formation of subcutaneous
nodules, often similar in histological appearance though
not in distribution to those found in rheumatoid disease. A
hallmark of these subcutaneous nodules is the existence
of the multinucleated giant cell, formed by fusion of
macrophages. The fusion of macrophages into multinucle-
ated giant cells is enhanced by stimulation of the adeno-
sine A1 receptor and is inhibited by activation of the A2
receptor [58,59].
The recent success of anti-TNF therapy highlights the role
of cytokines as important mediators of inflammatory activ-
ity. Not surprisingly, methotrexate, still one of the most
effective disease-modifying antirheumatic drugs for the
treatment of RA, acting through the release of adenosine,
also inhibits the production of TNF-α, although the adeno-
sine receptor involved in this action remains controversial
[60–63]. Modulation of cytokine production by adenosine
extends far beyond TNF-α and includes observable effects
on IL-6, IL-8, IL-10, IL-12, and macrophage inflammatory
protein-1α (MIP-1α) [40,64,65]. Cytokines themselves
can regulate the expression of adenosine receptors on
monocytic cells and thereby modulate adenosine-medi-
ated responses, as we and others have recently shown
[66,67]. Macrophage production of nitric oxide and nitric
oxide synthase is also inhibited by adenosine, probably via
A2B receptors [65,67].
Endothelial cells
Endothelial cells are effective transit barriers between
vessels and tissue and as such are notable in inflammation
not only because of their expression of adhesive mole-
cules, which allow leukocytes their access to inflammatory
sites. The effectiveness of this barrier function relies in
part on the preservation of impermeability to circulating
cells homing in to take part in inflammatory reactions in the
tissues. Adenosine enhances this barrier function by
decreasing enthothelial permeability via A2B receptor and
helps limit potential tissue damage [68,69]. Production of
inflammatory cytokines such as IL-6 and IL-8 and expres-
sion of adhesive molecules such as intercellular adhesion
molecule-1 (ICAM-1) and E-selectin by endothelial cells
are also suppressed by adenosine [70]. Another important
aspect of inflammation lies in the proliferation and migra-
tion of endothelial cells in the process of angiogenesis,
which is enhanced by the presence of adenosine, proba-
bly acting through A2 receptors [71–73]. Adenosine may
also induce apoptosis of endothelial cells, thus potentially
enhancing the extravasation of inflammatory fluids [74].
Humoral and cellular immune responses
Rheumatoid factor, or autoantibodies directed against the
Fc portion of IgG, is a hallmark of RA, although its exact
role in the pathogenesis of the disease has been debated.
The effect of methotrexate on the levels of circulating IgM
rheumatoid factors has also been controversial. While
some workers have reported no suppression of serum
rheumatoid factor levels with methotrexate treatment,
Alarcon et al. observed significant drops in the levels of
both IgM and IgA rheumatoid factors in methotrexate-
treated patients, and particularly of the concentration of
IgM rheumatoid factor in those who showed clinical
improvement [75]. These findings were confirmed by other
groups in studies done both in vivo and ex vivo [76–80],
although it is unclear whether this is a primary or sec-
ondary effect of adenosine.
T lymphocytes have received much attention in relation to
the pathogenesis of RA and opinions differ in their contri-
bution to the causation of the disease. The presence of
these cells in the affected synovium and the strong
ethnicity-dependent HLA–DR associations implicate T
lymphocytes as key players in the disease process. One
possible explanation of the beneficial actions of methotrex-
ate in RA is the diminution of both the size and reactivity of
the T-lymphocyte population. There are suggestions that
this may be accomplished by the induction of apoptosis in
activated T cells [24]. This suggestion is consistent with
the observations of reductions in peripheral blood T and B
lymphocyte populations after short-term methotrexate
treatment [81], and methotrexate induction of apoptosis in
inflammatory cells may be relevant to its antirheumatic
actions in vivo [82]. In contrast, significant increases in
the CD3- and CD4-positive peripheral blood cells and
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enhancement of stimulated lymphocyte proliferation have
been observed after long-term treatment with methotrex-
ate [83], and adenosine, acting through A2A and A2B
receptors, may play a role in T-cell deactivation [84,85].
Nonetheless, the role of these shifts in T-cell function and
trafficking in the pathogenesis of RA is unclear.
Phlogistic responses
Cytokines are messengers with major roles in inflammatory
and immune responses and have been targets of interest in
recent therapeutic developments in chronic arthritis, with
TNF-α and IL-1 as the focus of interest [86]. In animal
models of chronic arthritis, methotrexate was thought to be
useful in reducing the production of IL-1 [87,88]. In
support of these findings, clinical studies of RA patients
receiving methotrexate treatment have documented reduc-
tions in monocytic IL-1 production but not serum concen-
trations of IL-1 [89]. Others have disputed this view and
suggested that alterations in IL-1 responses were related
to diminutions in the ability of cells to respond to IL-1 rather
than to direct inhibition of its production, perhaps through
dose-dependent ligand binding [90–92].
Methotrexate is also known to suppress TNF activity by
suppressing TNF-induced nuclear factor-κB activation in
vitro, in part related to a reduction in the degradation and
inactivation of an inhibitor of this factor, IκBα, and proba-
bly related to the release of adenosine [93]. The genera-
tion of TNF-α by peripheral blood mononuclear cells is
suppressed by an adenosine kinase inhibitor, by virtue of
its ability to limit adenosine uptake and metabolism and
thereby enhance extracellular adenosine concentration
[94]. TNF-α synthesis in T cells and macrophages is sup-
pressed [95]. In the murine collagen-induced arthritis
model, in vivo intraperitoneal methotrexate treatment
reduced TNF serum levels and diminished TNF production
by splenic T cells and macrophages [96]. Methotrexate
suppresses the production of both TNF and IFN-γ by T-
cell-receptor-primed T lymphocytes from both healthy
human donors and RA patients [97]. In early RA, in which
the disease duration is less than 6 months, methotrexate
treatment is associated with a significant decrease of
TNF-α-positive CD4+ T cells, while the number of T cells
expressing the anti-inflammatory cytokine IL-10 increased
[98]. Methotrexate is also known to suppress the IL-6-
induced generation of reactive oxygen species in the syn-
oviocytes of RA patients [99]. Serum IL-6 levels have also
declined after methotrexate treatment in RA patients in
some studies [100]. Constantin et al. reported that ex vivo
treatment of peripheral blood monocytes with methotrex-
ate increased expression of IL-4 and IL-10 while IL-2 and
interferon-γ expression were decreased, suggesting that
the immunoregulatory role of methotrexate is also targeted
at adjusting the balance between Th1 proinflammatory
and Th2 anti-inflammatory cytokines [101]. Again, the mol-
ecular mechanism of these changes is unclear.
Conclusion
Our search for mechanisms governing the inflammatory
response has uncovered many facets relevant to the patho-
genesis of arthitic diseases. The success of methotrexate
as an antirheumatic agent rests on its many actions that
affect a wide variety of pathogenic mechanisms, many of
which are mediated by the release of adenosine. The mole-
cular mechanism for many of these phenomena is related
to the enhanced release of adenosine into the extracellular
space, where it can activate its receptors on relevant cell
types. In this respect, methotrexate is an excellent example
of how knowledge and continuing research in molecular
biology and pharmacology can be employed in the refine-
ment of existing medications originally used on an observa-
tional basis. Such understanding will form the basis for the
development of new and more effective therapy for the
treatment of rheumatic diseases.
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